Treatment of the Psychostimulant-Sensitized Animal Model of Schizophrenia

CNS Neuroscience and Therapeutics

Volumn 17, Issue 2, 2011, Pages 133-139

  Shuto, Takahide ^a   Nishi, Akinori ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Behavioral sensitization; Dopamine; Schizophrenia

Indexed keywords

AMPHETAMINE; COCAINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PSYCHOSTIMULANT AGENT; SEROTONIN 2A RECEPTOR; SEROTONIN 3 RECEPTOR;

DISEASE EXACERBATION; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; ENVIRONMENTAL FACTOR; EPIGENETICS; MESOCORTICAL DOPAMINERGIC SYSTEM; MESOLIMBIC DOPAMINERGIC SYSTEM; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; POSTSYNAPTIC POTENTIAL; PRESYNAPTIC POTENTIAL; REVIEW; SCHIZOPHRENIA; SENSITIZATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; HUMANS; RECEPTORS, DOPAMINE; SCHIZOPHRENIA;

EID: 79952659575     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00218.x     Document Type: Review

References (99)

1. Nestler EJ. Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2001;2:119-128.
2. Ujike H. Stimulant-induced psychosis and schizophrenia: The role of sensitization. Curr Psychiatry Rep 2002;4:177-184.
3. Curran C, Byrappa N, McBride A. Stimulant psychosis: Systematic review. Br J Psychiatry 2004;185:196-204.
4. Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 1987;91:415-433.
5. King GR, Joyner C, Ellinwood EH, Jr. Continuous or intermittent cocaine administration: Effects of amantadine treatment during withdrawal. Pharmacol Biochem Behav 1994;47:451-457.
6. King GR, Joyner C, Ellinwood EH, Jr. Continuous or intermittent cocaine administration: Effects of flupenthixol treatment during withdrawal. Pharmacol Biochem Behav 1994;49:883-889.
7. Vezina P, Stewart J. The effect of dopamine receptor blockade on the development of sensitization to the locomotor activating effects of amphetamine and morphine. Brain Res 1989;499:108-120.
8. Ujike H, Sato M. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann N Y Acad Sci 2004;1025:279-287.
9. Featherstone RE, Kapur S, Fletcher PJ. The amphetamine-induced sensitized state as a model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1556-1571.
10. Kuribara H, Uchihashi Y. Dopamine antagonists can inhibit methamphetamine sensitization, but not cocaine sensitization, when assessed by ambulatory activity in mice. J Pharm Pharmacol 1993;45:1042-1045.
11. Kuribara H, Uchihashi Y. Effects of dopamine antagonism on methamphetamine sensitization: Evaluation by ambulatory activity in mice. Pharmacol Biochem Behav 1994;47:101-106.
12. Vezina P. D1 dopamine receptor activation is necessary for the induction of sensitization by amphetamine in the ventral tegmental area. J Neurosci 1996;16:2411-2420.
13. Karper PE, De la Rosa H, Newman ER, et al. Role of D1-like receptors in amphetamine-induced behavioral sensitization: A study using D1A receptor knockout mice. Psychopharmacology (Berl) 2002;159:407-414.
14. Kuczenski R, Segal DS. Sensitization of amphetamine-induced stereotyped behaviors during the acute response. J Pharmacol Exp Ther 1999;288:699-709.
15. Moro H, Sato H, Ida I, et al. Effects of SKF-38393, a dopamine D1 receptor agonist on expression of amphetamine-induced behavioral sensitization and expression of immediate early gene arc in prefrontal cortex of rats. Pharmacol Biochem Behav 2007;87:56-64.
16. Hirabayashi M, Tadokoro S. Effect of chlorpromazine on mouse ambulatory activity sensitization caused by (+)-amphetamine. J Pharm Pharmacol 1993;45:481-483.
17. Futamura T, Akiyama S, Sugino H, Forbes A, McQuade RD, Kikuchi T. Aripiprazole attenuates established behavioral sensitization induced by methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1115-1119.
18. Kuribara H, Tadokoro S. Effects of YM-09151-2, a potent and selective dopamine D2 antagonist, on the ambulation-increasing effect of methamphetamine in mice. Jpn J Pharmacol 1990;52:489-492.
19. Kuribara H, Asami T, Ida I, Iijima Y, Tadokoro S. Effects of repeated MK-801 on ambulation in mice and in sensitization following methamphetamine. Psychopharmacology (Berl) 1992;108:271-275.
20. Ida I, Asami T, Kuribara H. Inhibition of cocaine sensitization by MK-801, a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: Evaluation by ambulatory activity in mice. Jpn J Pharmacol 1995;69:83-90.
21. Li Y, White FJ, Wolf ME. Pharmacological reversal of behavioral and cellular indices of cocaine sensitization in the rat. Psychopharmacology (Berl) 2000;151:175-183.
22. De Montis MG, Gambarana C, Ghiglieri O, Tagliamonte A. Reversal of stable behavioural modifications through NMDA receptor inhibition in rats. Behav Pharmacol 1995;6:562-567.
23. Barrett AC, Miller JR, Dohrmann JM, Caine SB. Effects of dopamine indirect agonists and selective D1-like and D2-like agonists and antagonists on cocaine self-administration and food maintained responding in rats. Neuropharmacology 2004;47(Suppl 1):256-273.
24. Caine SB, Negus SS, Mello NK, Bergman J. Effects of dopamine D(1-like) and D(2-like) agonists in rats that self-administer cocaine. J Pharmacol Exp Ther 1999;291:353-360.
25. Self DW, Barnhart WJ, Lehman DA, Nestler EJ. Opposite modulation of cocaine-seeking behavior by D1- and D2-like dopamine receptor agonists. Science 1996;271:1586-1589.
26. Ago Y, Nakamura S, Baba A, Matsuda T. Neuropsychotoxicity of abused drugs: Effects of serotonin receptor ligands on methamphetamine- and cocaine-induced behavioral sensitization in mice. J Pharmacol Sci 2008;106:15-21.
27. Shuto T, Kuroiwa M, Hamamura M, et al. Reversal of methamphetamine-induced behavioral sensitization by repeated administration of a dopamine D1 receptor agonist. Neuropharmacology 2006;50:991-997.
28. Shuto T, Seeman P, Kuroiwa M, Nishi A. Repeated administration of a dopamine D1 receptor agonist reverses the increased proportions of striatal dopamine D1High and D2High receptors in methamphetamine-sensitized rats. Eur J Neurosci 2008;27:2551-2557.
29. Bowers MS, McFarland K, Lake RW, et al. Activator of G protein signaling 3: A gatekeeper of cocaine sensitization and drug seeking. Neuron 2004;42:269-281.
30. Arai I, Shimazoe T, Yoshimatsu A, Inoue H, Shibata S, Watanabe S. Vulnerability of synaptic plasticity in the striatum of methamphetamine-sensitized rats. Jpn J Pharmacol 1998;78:105-108.
31. Yoshimatsu A, Shimazoe T, Kawashimo A, et al. Effects of adenosine A1- and A2A-receptor agonists on enhancement of dopamine release from the striatum in methamphetamine-sensitized rats. Jpn J Pharmacol 2001;86:254-257.
32. Niznik HB. Dopamine receptors: Molecular structure and function. Mol Cell Endocrinol 1987;54:1-22.
33. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987;1:133-152.
34. George SR, Watanabe M, Di Paolo T, Falardeau P, Labrie F, Seeman P. The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology 1985;117:690-697.
35. Seeman P, Tallerico T, Ko F, Tenn C, Kapur S. Amphetamine-sensitized animals show a marked increase in dopamine D2 high receptors occupied by endogenous dopamine, even in the absence of acute challenges. Synapse 2002;46:235-239.
36. Levy AD, Kim JJ, Ellison GD. Chronic amphetamine alters D-2 but not D-1 agonist-induced behavioral responses in rats. Life Sci 1988;43:1207-1213.
37. Ujike H, Akiyama K, Otsuki S. D-2 but not D-1 dopamine agonists produce augmented behavioral response in rats after subchronic treatment with methamphetamine or cocaine. Psychopharmacology (Berl) 1990;102:459-464.
38. Saklayen SS, Mabrouk OS, Pehek EA. Negative feedback regulation of nigrostriatal dopamine release: Mediation by striatal D1 receptors. J Pharmacol Exp Ther 2004;311:342-348.
39. Mark KA, Soghomonian JJ, Yamamoto BK. High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J Neurosci 2004;24:11449-11456.
40. Crawford CA, Choi FY, Kohutek JL, Yoshida ST, McDougall SA. Changes in PKA activity and Gs alpha and Golf alpha levels after amphetamine- and cocaine-induced behavioral sensitization. Synapse 2004;51:241-248.
41. Borgkvist A, Fisone G. Psychoactive drugs and regulation of the cAMP/PKA/DARPP-32 cascade in striatal medium spiny neurons. Neurosci Biobehav Rev 2007;31:79-88.
42. Carter CJ, Pycock CJ. Behavioural and biochemical effects of dopamine and noradrenaline depletion within the medial prefrontal cortex of the rat. Brain Res 1980;192:163-176.
43. Pycock CJ, Carter CJ, Kerwin RW. Effect of 6-hydroxydopamine lesions of the medial prefrontal cortex on neurotransmitter systems in subcortical sites in the rat. J Neurochem 1980;34:91-99.
44. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 1991;148:1474-1486.
45. Fletcher PJ, Tenn CC, Rizos Z, Lovic V, Kapur S. Sensitization to amphetamine, but not PCP, impairs attentional set shifting: Reversal by a D1 receptor agonist injected into the medial prefrontal cortex. Psychopharmacology (Berl) 2005;183:190-200.
46. McLean SL, Idris NF, Woolley ML, Neill JC. D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia. Eur Neuropsychopharmacol 2009;19:440-450.
47. Wolf ME. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol 1998;54:679-720.
48. Karler R, Calder LD, Chaudhry IA, Turkanis SA. Blockade of "reverse tolerance" to cocaine and amphetamine by MK-801. Life Sci 1989;45:599-606.
49. Reid MS, Hsu K, Jr., Berger SP. Cocaine and amphetamine preferentially stimulate glutamate release in the limbic system: Studies on the involvement of dopamine. Synapse 1997;27:95-105.
50. Artola A, Singer W. Long-term depression of excitatory synaptic transmission and its relationship to long-term potentiation. Trends Neurosci 1993;16:480-487.
51. Calabresi P, Picconi B, Tozzi A, Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 2007;30:211-219.
52. Thomas MJ, Kalivas PW, Shaham Y. Neuroplasticity in the mesolimbic dopamine system and cocaine addiction. Br J Pharmacol 2008;154:327-342.
53. Centonze D, Costa C, Rossi S, et al. Chronic cocaine prevents depotentiation at corticostriatal synapses. Biol Psychiatry 2006;60:436-443.
54. Tashev R, Moura PJ, Venkitaramani DV, et al. A substrate trapping mutant form of striatal-enriched protein tyrosine phosphatase prevents amphetamine-induced stereotypies and long-term potentiation in the striatum. Biol Psychiatry 2009;65:637-645.
55. Pu L, Liu QS, Poo MM. BDNF-dependent synaptic sensitization in midbrain dopamine neurons after cocaine withdrawal. Nat Neurosci 2006;9:605-607.
56. Li Y, Kauer JA. Repeated exposure to amphetamine disrupts dopaminergic modulation of excitatory synaptic plasticity and neurotransmission in nucleus accumbens. Synapse 2004;51:1-10.
57. Wang Z, Kai L, Day M, et al. Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. Neuron 2006;50:443-452.
58. Centonze D, Grande C, Saulle E, et al. Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. J Neurosci 2003;23:8506-8512.
59. Przegalinski E, Siwanowicz J, Baran L, Filip M. Activation of serotonin (5-HT)1A receptors inhibits amphetamine sensitization in mice. Life Sci 2000;66:1011-1019.
60. Auclair A, Drouin C, Cotecchia S, Glowinski J, Tassin JP. 5-HT2A and alpha1b-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants. Eur J Neurosci 2004;20:3073-3084.
61. Yoo JH, Cho JH, Yu HS, et al. Involvement of 5-HT receptors in the development and expression of methamphetamine-induced behavioral sensitization: 5-HT receptor channel and binding study. J Neurochem 2006;99:976-988.
62. Davidson C, Lee TH, Xiong Z, Ellinwood EH. Ondansetron given in the acute withdrawal from a repeated cocaine sensitization dosing regimen reverses the expression of sensitization and inhibits self-administration. Neuropsychopharmacology 2002;27:542-553.
63. Davidson C, Gopalan R, Ahn C, et al. Reduction in methamphetamine induced sensitization and reinstatement after combined pergolide plus ondansetron treatment during withdrawal. Eur J Pharmacol 2007;565:113-118.
64. Zhang X, Mi J, Wetsel WC, et al. PI3 kinase is involved in cocaine behavioral sensitization and its reversal with brain area specificity. Biochem Biophys Res Commun 2006;340:1144-1150.
65. Zhang X, Lee TH, Davidson C, Lazarus C, Wetsel WC, Ellinwood EH. Reversal of cocaine-induced behavioral sensitization and associated phosphorylation of the NR2B and GluR1 subunits of the NMDA and AMPA receptors. Neuropsychopharmacology 2007;32:377-387.
66. Chen Q, Lee TH, Wetsel WC, et al. Reversal of cocaine sensitization-induced behavioral sensitization normalizes GAD67 and GABAA receptor alpha2 subunit expression, and PKC zeta activity. Biochem Biophys Res Commun 2007;356:733-738.
67. Davidson C, Lazarus C, Xiong X, Lee TH, Ellinwood EH. 5-HT2 receptor antagonists given in the acute withdrawal from daily cocaine injections can reverse established sensitization. Eur J Pharmacol 2002;453:255-263.
68. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002;441:137-140.
69. Rasmussen K, Stockton ME, Czachura JF. The 5-HT3 receptor antagonist zatosetron decreases the number of spontaneously active A10 dopamine neurons. Eur J Pharmacol 1991;205:113-116.
70. Prisco S, Pessia M, Ceci A, Borsini F, Esposito E. Chronic treatment with DAU 6215, a new 5-HT3 receptor antagonist, causes a selective decrease in the number of spontaneously active dopaminergic neurons in the rat ventral tegmental area. Eur J Pharmacol 1992;214:13-19.
71. Invernizzi R, Pozzi L, Samanin R. Selective reduction of extracellular dopamine in the rat nucleus accumbens following chronic treatment with DAU 6215, a 5-HT3 receptor antagonist. Neuropharmacology 1995;34:211-215.
72. Sorensen SM, Humphreys TM, Palfreyman MG. Effect of acute and chronic MDL 73, 147EF, a 5-HT3 receptor antagonist, on A9 and A10 dopamine neurons. Eur J Pharmacol 1989;163:115-118.
73. Minabe Y, Ashby CR, Jr., Wang RY. Effects produced by acute and chronic treatment with granisetron alone or in combination with haloperidol on midbrain dopamine neurons. Eur Neuropsychopharmacol 1992;2:127-133.
74. Palfreyman MG, Schmidt CJ, Sorensen SM, et al. Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function. Psychopharmacology (Berl) 1993;112:S60-S67.
75. Liu W, Thielen RJ, McBride WJ. Effects of repeated daily treatments with a 5-HT3 receptor antagonist on dopamine neurotransmission and functional activity of 5-HT3 receptors within the nucleus accumbens of Wistar rats. Pharmacol Biochem Behav 2006;84:370-377.
76. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: A possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001;76:1521-1531.
77. Moghaddam B, Bunney BS. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: An in vivo microdialysis study. J Neurochem 1990;54:1755-1560.
78. Volonte M, Monferini E, Cerutti M, Fodritto F, Borsini F. BIMG 80, a novel potential antipsychotic drug: Evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J Neurochem 1997;69:182-190.
79. Li XM, Perry KW, Wong DT, Bymaster FP. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology (Berl) 1998;136:153-161.
80. Kuroki T, Meltzer HY, Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 1999;288:774-781.
81. Bortolozzi A, Diaz-Mataix L, Scorza MC, Celada P, Artigas F. The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J Neurochem 2005;95:1597-1607.
82. Schmidt CJ, Fadayel GM. The selective 5-HT2A receptor antagonist, MDL 100, 907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol 1995;273:273-279.
83. Engleman EA, Rodd ZA, Bell RL, Murphy JM. The role of 5-HT3 receptors in drug abuse and as a target for pharmacotherapy. CNS Neurol Disord Drug Targets 2008;7:454-467.
84. Blank T, Zwart R, Nijholt I, Spiess J. Serotonin 5-HT2 receptor activation potentiates N-methyl-D-aspartate receptor-mediated ion currents by a protein kinase C-dependent mechanism. J Neurosci Res 1996;45:153-160.
85. Ronde P, Nichols RA. High calcium permeability of serotonin 5-HT3 receptors on presynaptic nerve terminals from rat striatum. J Neurochem 1998;70:1094-1103.
86. Funahashi M, Mitoh Y, Matsuo R. Activation of presynaptic 5-HT3 receptors facilitates glutamatergic synaptic inputs to area postrema neurons in rat brain slices. Methods Find Exp Clin Pharmacol 2004;26:615-622.
87. Ago Y, Nakamura S, Uda M, et al. Attenuation by the 5-HT1A receptor agonist osemozotan of the behavioral effects of single and repeated methamphetamine in mice. Neuropharmacology 2006;51:914-922.
88. Ago Y, Nakamura S, Kajita N, et al. Ritanserin reverses repeated methamphetamine-induced behavioral and neurochemical sensitization in mice. Synapse 2007;61:757-763.
89. King GR, Xiong Z, Ellinwood EH, Jr. Blockade of the expression of sensitization and tolerance by ondansetron, a 5-HT3 receptor antagonist, administered during withdrawal from intermittent and continuous cocaine. Psychopharmacology (Berl) 1998;135:263-269.
90. King GR, Xiong Z, Douglass S, Ellinwood EH. Long-term blockade of the expression of cocaine sensitization by ondansetron, a 5-HT(3) receptor antagonist. Eur J Pharmacol 2000;394:97-101.
91. Park HJ, Cui FJ, Hwang JY, Kang UG. Effects of clozapine on behavioral sensitization induced by cocaine. Psychiatry Res 2010;175:165-170.
92. Seeman P. All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2 Receptors. CNS Neurosci Ther 2010. doi:
93. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-1308.
94. Takahata R, Moghaddam B. Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine. Neuropsychopharmacology 2003;28:1117-1124.
95. Sams-Dodd F. A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine. Neuropsychopharmacology 1998;18:293-304.
96. Martinez ZA, Ellison GD, Geyer MA, Swerdlow NR. Effects of sustained phencyclidine exposure on sensorimotor gating of startle in rats. Neuropsychopharmacology 1999;21:28-39.
97. Kaneko Y, Kashiwa A, Ito T, Ishii S, Umino A, Nishikawa T. Selective serotonin reuptake inhibitors, fluoxetine and paroxetine, attenuate the expression of the established behavioral sensitization induced by methamphetamine. Neuropsychopharmacology 2007;32:658-664.
98. Bebawy D, Marquez P, Samboul S, Parikh D, Hamid A, Lutfy K. Orphanin FQ/nociceptin not only blocks but also reverses behavioral adaptive changes induced by repeated cocaine in mice. Biol Psychiatry 2010;68:223-230.
99. Solinas M, Chauvet C, Thiriet N, El Rawas R, Jaber M. Reversal of cocaine addiction by environmental enrichment. Proc Natl Acad Sci U S A 2008;105:17145-17150.